DAPTOMYCIN FOR INJECTION POWDER FOR SOLUTION

Country: Kanada

Tungumál: enska

Heimild: Health Canada

Virkt innihaldsefni:

DAPTOMYCIN

Fáanlegur frá:

ACCORD HEALTHCARE INC

ATC númer:

J01XX09

INN (Alþjóðlegt nafn):

DAPTOMYCIN

Skammtar:

500MG

Lyfjaform:

POWDER FOR SOLUTION

Samsetning:

DAPTOMYCIN 500MG

Stjórnsýsluleið:

INTRAVENOUS

Einingar í pakka:

15G/50G

Gerð lyfseðils:

Prescription

Lækningarsvæði:

CYCLIC LIPOPEPTIDES

Vörulýsing:

Active ingredient group (AIG) number: 0152298001; AHFS:

Leyfisstaða:

APPROVED

Leyfisdagur:

2020-10-01

Vara einkenni

PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
DAPTOMYCIN FOR INJECTION
Lyophilized Powder for Solution, For Intravenous Use Only
500 mg/vial
Antibacterial Agent
Accord Healthcare Inc.
3535 boul. St-Charles, Suite 704
Kirkland, Quebec
H9H 5B9
Date of Revision:
August 31, 2020
Submission Control Number:
242602
_Page 2 of 60_
_Product Monograph of Daptomycin for Injection _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................... 3
SUMMARY PRODUCT INFORMATION
........................................................................
3
INDICATIONS AND CLINICAL USE
..............................................................................
3
CONTRAINDICATIONS
...................................................................................................
4
WARNINGS AND PRECAUTIONS
..................................................................................
4
ADVERSE REACTIONS
.................................................................................................
11
DRUG INTERACTIONS
.................................................................................................
19
DOSAGE AND ADMINISTRATION
.............................................................................
22
ACTION AND CLINICAL PHARMACOLOGY
............................................................ 27
STORAGE AND STABILITY
.........................................................................................
32
SPECIAL HANDLING INSTRUCTIONS
.......................................................................
33
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................................ 33
PART II: SCIENTIFIC INFORMATION
..............................................................................
34
PHARMACEUTICAL INFORMATION
.........................................................................
34
CLINICAL TRIALS
.........................................................................................................
35
DETA